Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920665 | 0.83 | SRC (0.41) | SRCIDO1QPCTQPCTLCYP2E1 | |
| SCHEMBL1155489 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLTDO2 | |
| SCHEMBL31391522 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLTDO2 | |
| SCHEMBL399396 | 0.75 | NUDT1 (0.48) | SRCIDO1QPCTQPCTLTDO2 | |
| SCHEMBL1129049 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLTDO2 | |
| SCHEMBL1015306 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLL3MBTL1 | |
| SCHEMBL24198354 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLTBXAS1 | |
| SCHEMBL21672756 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTL | |
| SCHEMBL24983628 | 0.75 | SRC (0.44) | SRCIDO1QPCTQPCTLCYP3A4 | |
| Hydrochloric Acid SCHEMBL30404265 | 0.73 | NUDT1 (0.47) | SRCIDO1QPCTQPCTLTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023076218-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022007966-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川海思科制药有限公司 | 2022-01-13 | — | — | WO | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECKA/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-10011606-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-07-03 | — | — | US | disclosed |
| US-20170291903-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-12 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20140155406-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-06-05 | — | — | US | disclosed |
| EP-2734523-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013010869-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK-INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE1B, PDE1A | SRC 4214/4885IDO1 69/4885QPCT 1314/4885 |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | SRC 3802/4885IDO1 116/4885QPCT 2688/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | SRC 3802/4885IDO1 116/4885QPCT 2688/4885 |
| US-20140155406-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK INHIBITORS | BTK, ABL1, SYK | SRC 20/4885IDO1 736/4885QPCT 2561/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | SRC 3802/4885IDO1 116/4885QPCT 2688/4885 |
| US-20170291903-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | SRC 3802/4885IDO1 116/4885QPCT 2688/4885 |
| US-10011606-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | SRC 3802/4885IDO1 116/4885QPCT 2688/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | SRC 4355/4885IDO1 197/4885QPCT 1023/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | SRC 4639/4885IDO1 66/4885QPCT 1988/4885 |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE4A, PDE1A | SRC 3962/4885IDO1 212/4885QPCT 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.